Accuracy of lipid profiles in the hospital setting: Impact on the initiation of cholesterol-lowering therapy

被引:0
|
作者
Keilson, L
机构
来源
关键词
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Hospitalization for an acute ec ent. such as myocardial infarction. is an opportune time for screening lipids, counseling patients, and advising them about treatments. Physicians frequently fail to seize these "windows of opportunity" that hospitalization presents. The hospital setting may be the best time to screen a patient's lipid levels and systems can be set up to accomplish this in a timely fashion. There are certain illnesses, procedures, and conditions under which a patient's lipids may be altered and these should be considered ui hcn about to undertake screening. The conventional Freidewald test appears to be as reliable as newer lipid-screening measures. Using this test, nonfasting lipids can reliably predict patients with elevated cholesterol.
引用
收藏
页码:S18 / S20
页数:3
相关论文
共 50 条
  • [31] Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting
    Lacy, CR
    Swartz, CD
    Moylan, DM
    Bueno, M
    Suh, DC
    Barone, JA
    Kostis, JB
    CIRCULATION, 1998, 98 (17) : 45 - 46
  • [32] The impact of aggressive lipid lowering therapy upon cholesterol biosynthesis and absorption
    Bláha, V
    Hyspler, R
    Bláha, M
    Solichová, D
    Havel, E
    Vyroubal, P
    Zadák, Z
    Maly, J
    ATHEROSCLEROSIS: RISK FACTORS, DIAGNOSIS, AND TREATMENT, 2002, : 267 - 271
  • [33] Evaluation of lipid and cholesterol-lowering effect of bioflavonoids from bergamot extract
    Ballistreri, Gabriele
    Amenta, Margherita
    Fabroni, Simona
    Consoli, Valeria
    Grosso, Salvo
    Vanella, Luca
    Sorrenti, Valeria
    Rapisarda, Paolo
    NATURAL PRODUCT RESEARCH, 2021, 35 (23) : 5378 - 5383
  • [34] Statin trials and goals of cholesterol-lowering therapy after AMI
    Pedersen, TR
    AMERICAN HEART JOURNAL, 1999, 138 (02) : S177 - S182
  • [35] Risk factors for stroke and the effect of cholesterol-lowering therapy with pravastatin
    West, M
    White, H
    Simes, R
    Kirby, A
    Anderson, N
    Hankey, G
    Tonkin, A
    JOURNAL OF HYPERTENSION, 2000, 18 : S17 - S17
  • [36] The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm
    Luetjohann, Dieter
    Stellaard, Frans
    Mulder, Monique T.
    Sijbrands, Eric J. G.
    Weingaertner, Oliver
    PHARMACOLOGY & THERAPEUTICS, 2019, 199 : 111 - 116
  • [37] CHOLESTEROL-LOWERING THERAPY MAY RETARD THE PROGRESSION OF DIABETIC NEPHROPATHY
    LAM, KSL
    CHENG, IKP
    JANUS, ED
    PANG, RWC
    DIABETOLOGIA, 1995, 38 (05) : 604 - 609
  • [39] The Success of Cholesterol-lowering Treatment goes Beyond Pharmacological Therapy
    Ibanez, T. L. P.
    Capeletti, J. T.
    Barbosa, R. R.
    Cestari, P. F.
    Peres, G. M. T. L. S. R.
    Bertolami, A.
    Faludi, A. A.
    Araujo, D. B.
    Zatz, H. P.
    Bertolami, M. C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (03) : 36 - 36
  • [40] Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy
    Hoenig, MR
    Rolfe, BE
    Campbell, JH
    ATHEROSCLEROSIS, 2006, 184 (02) : 247 - 254